Real‐world data for precision cancer medicine—A European perspective

Abstract

AbstractLeveraging real‐world data (RWD) for drug access is necessary to overcome a key challenge of modern precision oncology: tackling numerous low‐prevalence oncogenic mutations across cancers. Withholding a potentially active medication in patients with rare mutations for the sake of control chemotherapy or “best” supportive care is neither practicable nor ethically justifiable anymore, particularly as RWD could meanwhile be used instead, according to scientific principles outlined by the US Food and Drug Administration, European Medicines Agency and other stakeholders. However, practical implementation varies, with occasionally opposite recommendations based on the same evidence in different countries. In the face of growing need for precision drugs, more transparency of evaluation, a priori availability of guidance for the academia and industry, as well as a harmonized framework for health technology assessment across the European Union (EU) are imperative. These could in turn trigger infrastructural changes in national and pan‐European registries, cancer management guidelines (e.g., frequency of routine radiologic restaging, inclusion of patient‐reported outcomes), and the health data space, to ensure conformity with declared standards and facilitate extraction of RWD sets (including patient‐level data) suitable for approval and pricing with minimal effort. For an EU‐wide unification of precision cancer medicine, collective negotiation of drug supply contracts and funding solidarity would additionally be required to handle the financial burden. According to experience from pivotal European programs, off‐label use could potentially also be harmonized across EU‐states to accelerate availability of novel drugs, streamline collection of valuable RWD, and mitigate related costs through wider partnerships with pharmaceutical companies.